Regulatory tailwinds for psychedelic medicine
The guest argued that the incoming Trump administration and RFK Jr. will likely expedite FDA approvals for psychedelic treatments, potentially triggering big pharma acquisitions.
The argument
Clinical trials for substances like psilocybin and ibogaine have shown strong efficacy for PTSD and depression. As these clinical trials progress, major pharmaceutical companies facing revenue declines in traditional SSRIs may look to acquire these biotech players.
The thesis, stress-tested
✓ What validates it
- ✓FDA approval of a major psychedelic drug
- ✓Acquisition of a clinical-stage psychedelic company by a major pharmaceutical firm
▸ Risks discussed
- ▸Binary clinical trial outcomes
- ▸Lack of current revenue for clinical-stage companies
- ▸Potential generic or off-patent competition flooding the market
Hear it yourself
"the options market and the passive bid, and the unlimited liquidity, this is a completely different stock market than it ever was. And thus, we return back to my comment today that it's a digital casino on cocaine because that is really what it's become. Welcome to Thoughtful Money. I'm Thoughtful Money founder and your host, Adam Taggart, welcoming you here for a very special discussion with Chris Irons. Those of you who may not know Chris, he's the author and publisher of Quoth the Raven Fringe Finance."
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE